ArticleInfectious diseases and therapy2020
Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All.
Article in Infectious diseases and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Unlocking the Potential of RNA Sequencing in COVID-19: Toward Accurate Diagnosis and Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
- Functional characterization and unraveling the structural determinants of novel steroid hydroxylase CYP154C7 fromHeliyon · 2024Article
- In-hospital survival of critically ill COVID-19 patients treated with glucocorticoids: a multicenter real-world data study.Scientific reports · 2024Article
- Possible modulating functions of probioticFrontiers in cellular and infection microbiology · 2023Review
- Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19.The Lancet. Digital health · 2022Article
- Deep RNA sequencing of intensive care unit patients with COVID-19.Scientific reports · 2022Article
- Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.The Lancet. Digital health · 2022Observational
- Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations.Diabetology & metabolic syndrome · 2022Review
- Dental Healthcare Amid the COVID-19 Pandemic.International journal of environmental research and public health · 2021Review
- Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications.International journal of molecular sciences · 2021Review
- Steroid use in elderly critically ill COVID-19 patients.The European respiratory journal · 2021Article
- Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids.Clinical therapeutics · 2021Article
- Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment.SN comprehensive clinical medicine · 2021Article
- Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?F1000Research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.